Latest news for Karman Holdings (NYSE:KRMN) Stock

Karman Holdings Inc specializes in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile and defense, and space programs. Its integrated payload protection, propulsion, and interstage system solutions are deployed across a wide variety of existing and emerging programs supporting important Department of Defense (DoD) and space sector initiatives. Its engineered solutions are organized into three key families: Payload Protection and Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company's solutions are deployed across three growing, core end markets: Hypersonics & Strategic Missile Defense, Missile & Integrated Defense Systems, and Space & Launch.

Karman Holdings Inc

Senator Elizabeth Warren (D-Mass.) is targeting Walt Disney Company's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) proposed tie-up with FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) that could change <a href="https://www.benzinga.com/topic/streaming">the streaming sector.</a>
What Happened: In a letter to the Department of Justice, Warren asks for close scrutiny<a href="https://www.benzinga.com/25/01/42816545/fubotv-and-disney-near-merger-to-create-second-largest-digital-tv-provider-shares-soar-report"> on the deal </a>due to antitrust concerns and fear that consumers will end up paying more for sports streaming content in the long run.
"This proposed acquisition raises significant concerns under antitrust law, would give Disney increased market power and incentives to increase costs for viewers, and should be regarded as another data point in Disney's history of anticompetitive behavior," Warren said in the letter.
Warren highlighted that Disney's deal with Fubo resolves a previous lawsuit Fubo filed against Disney, Fox and Warner Bros. Discovery over a joint venture called Venu Sports. Warren previously wrote the DOJ on Venu Sports.
"Disney's proposed acquisition of Fubo appears to allow Disney to simultaneously circumvent the lawsuit while gobbling up a competitor."
Warren said Disney is attempting to "purchase its way around antitrust law."
With the tie-up with Fubo, Disney would dominate the sports streaming market, Warren said.
The Senator said Disney's acquisition will decrease competition and could violate antitrust law.
"Disney has proposed a plan to acquire its competitor, and, in the process become an even more powerful force in an already highly-concentrated market."
Warren said Disney has long forced companies to carry less desirable content in order to get access to the highly coveted ESPN sports network. This practice has led to consumers paying more for streaming and cable content.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/01/43169631/disney-analyst-sees-flat-disney-growth-in-q1-after-netflixs-record-quarter-but-remains-bullish">Disney Analyst Sees Flat Disney+ Growth In Q1 After Netflix&#8217;s Record Quarter, But Remains Bullish</a>
Why It's Important: Warren's letter comes after Disney previously announced it would merge Hulu + Live TV with Fubo and own 70% of the combined company. The deal also ended the pending launch of Venu Sports and saw Fubo and Disney end litigation.
News of Warren's letter to the DOJ comes as a judge declined to dismiss a lawsuit against Disney by investors, as reported by The Hollywood Reporter.
The investor lawsuit centers on past claims made by former Disney CEO Bob Chapek about the Disney+ streaming platform. Chapek allegedly hid streaming costs and overstated the ability for the unit to grow subscribers and become profitable.
Among the items in the lawsuit, filed in 2023, is Disney&#8217;s plan to grow its Disney+ subscriber total to 230 million by 2024. The company's total stood at 124.6 million Disney+ core subscribers as of December 2024.
The lawsuit also targets Disney's reorganization plans and changes to its original content and the shortened theatrical window for movies to hit streaming platforms.
Bob Iger replaced Chapek as CEO in November 2022. Iger cut streaming content spending and withdrew subscriber guidance when he took over.
The class action lawsuit targets the period of December 2020 to May 2023 when Disney stock dropped by around 55%.  
With news of the case moving forward, along with Warren's letter to the Department of Justice, Disney may see negative headlines in the coming months.
Price Action: Disney stock is down 1.3% to $109.87 on Thursday versus a 52-week trading range of $83.91 to $123.74. Disney stock is up 0.4% over the last year.
Fubo stock is down 1.8% to $3.79 on Thursday versus a 52-week trading range of $1.10 to $6.45. Fubo stock is up 90% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/42857294/fubo-gets-fairy-tale-outcome-analyst-says-disney-deal-lowers-risks-overhang-on-stock">Fubo Gets &#8216;Fairy Tale Outcome&#8217;: Analyst Says Disney Deal Lowers Risks, Overhang On Stock</a></li>
</ul>
Image: Shutterstock

Entertainment

Politics

Legal

Sports

Trading Ideas

FUBO

Elizabeth Warren Slams Disney, Fubo Deal In DOJ Letter: 'Another Data Point In History Of Anticompetitive Behavior'

<a href="https://www.kyivpost.com/post/47529" title="https://www.kyivpost.com/post/47529">https://www.kyivpost.com/post/47529</a>

Macro Economic Events

News

Global

Economics

"US Reportedly Halts Weapon Sales To Ukraine; A Ukrainian Lawmaker From Verkhovna Rada's Defense Committee Said Weapon Deliveries Have Stopped, And The Reason Is Unclear" - Kyiv Post

Cryptocurrency markets remain bullish on Thursday, fueled by optimism over <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43827841/bitcoin-ethereum-xrp-dogecoin-rebound-92000-key-downside-support-until-97000-98500-is-reclaimed-analysts-say">potential altcoin ETFs</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$98,414.37</td>
<td>+2.6%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,753.73</td>
<td>+1.7%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$174.54</td>
<td>+3.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.71</td>
<td>+1.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2543</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001555</td>
<td>+1.7%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 8.6% and daily active addresses falling by 11.6%. Transactions greater than $100,000 are down from 10,134 to 9,587 in a single day. Exchanges netflows are up by 583.7%.</li>
<li>Coinglass data reports 94,182 traders were liquidated in the past 24 hours for $166.31 million.</li>
<li>Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1892608149955223675">stated</a> that $13.5 billion left the cryptocurrency market in the past week, reflecting a decline in capital inflows.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43857831/sec-scales-back-crypto-enforcement-expands-focus-to-cyber-fraud">SEC Scales Back Crypto Enforcement, Expands Focus To Cyber Fraud</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43852658/bitcoin-ethereum-face-downside-risk-as-institutional-demand-fades-jpmorgan-says">Bitcoin, Ethereum Face Downside Risk As Institutional Demand Fades, JPMorgan Says</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43847052/vitalik-buterin-criticizes-blockchain-casinos-suggests-ethereum-wont-follow-solanas-approach-to-meme-coins">Vitalik Buterin Criticizes Blockchain &#8216;Casinos,&#8217; Suggests Ethereum Won&#8217;t Follow Solana&#8217;s Approach To Meme Coins</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43855374/studying-bitcoin-will-strengthen-us-czech-central-bank-governor-says">Studying Bitcoin Will Strengthen Us, Czech Central Bank Governor Says</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43839496/nigeria-hits-binance-with-81-billion-lawsuit-alleging-economic-damages-and-unpaid-taxes">Nigeria Hits Binance With $81 Billion Lawsuit Alleging Economic Damages And Unpaid Taxes</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Story (CRYPTO: IP)</td>
<td>&nbsp;$3.83</td>
<td>+43.2%</td>
</tr>
<tr>
<td>Pyth Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PYTH</a>)</td>
<td>$0.2572</td>
<td>+26.2%</td>
</tr>
<tr>
<td>Berachain (CRYPTO: BERA)</td>
<td>$8.13</td>
<td>+24.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin heading towards $100,000, crypto trader Kevin noted that it's tough to be bearish on the BTC chart.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hard to be bearish on this chart folks &#8211; <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> vs S&amp;P <a href="https://t.co/CjPWIV5xlT">pic.twitter.com/CjPWIV5xlT</a>
&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1892558728664092933?ref_src=twsrc%5Etfw">February 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader Mayne <a href="https://x.com/Tradermayne/status/1892653600037601364">highlighted</a> key levels: Bitcoin above $99,500 and Ethereum above $2,850 as crucial for a potential mean reversion move. 
Meanwhile, trader CJ is <a href="https://x.com/CJ900X/status/1892653890711040023">watching</a> for a reaction at $98,826 and looking to buy dips around $96,000–$96,500, expecting a setup toward $105,000.
Network Economist Timothy Peterson <a href="https://x.com/nsquaredvalue/status/1892643019058266616">emphasized</a> Bitcoin cycle timing: in a bull market period of 9 months, traders can expect to double money, with an average annualized return of 152%. In a bear market of 34 months, returns slow significantly with an average annualized return of 28%, making the doubling time much longer.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43858235/bitcoin-down-6-over-the-past-month-why-is-btc-not-going-up">Bitcoin Down 6% Over The Past Month: Why Is BTC Not Going Up?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$MKR

$PYTH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Continue Slow Walk Up

Management

NMRK

Stephen Merkel Appointed Chairman Of Newmark's Board Of Directors

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 1% on Thursday.
The Dow traded down 1.11% to 44,132.13 while the NASDAQ fell 0.54% to 19,947.18. The S&amp;P 500 also fell, dropping, 0.49% to 6,114.11.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Energy shares jumped by 0.8% on Thursday.
In trading on Thursday, financials shares fell by 1.6%.
Top Headline
Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) shares fell more than 5% on Thursday following the release of quarterly results.
The company reported fourth-quarter FY25 sales growth of 4.1% year-on-year to $180.55 billion, beating the analyst consensus estimate of $180.01 billion. The retailer reported that in the fourth quarter of 2025, adjusted EPS was 66 cents, beating the consensus estimate of 64 cents.
Walmart said it sees first-quarter FY26 sales growth of 3% – 4% in CC and adjusted EPS of $0.57 – $0.58 against an estimate of $0.64. For FY26 Walmart expects sales to grow 3% – 4% in CC and an adjusted EPS of $2.50 – $2.60, below the $2.76 estimate.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares shot up 129% to $0.7558.</li>
<li>Shares of Xos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>)got a boost, surging 95% to $6.21.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) shares were also up, gaining 84% to $0.2457. Volato Group disclosed that Vaunt, its fast-growing private aviation platform, has reached a major milestone, reporting $1.5 million in annual recurring revenue within its first year, a 50% surge since mid-2024.</li>
</ul>
Equities Trading DOWN
<ul>
<li>WORK Medical Technology Group LTD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) shares dropped 51% to $1.1994.</li>
<li>Shares of Cycurion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) were down 46% to $1.60.</li>
<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) was down, falling 35% to $5.97 after the company missed its fourth-quarter sales estimate and stated they have expectations for a difficult macroeconomic environment in 2025.</li>
</ul>
Commodities In commodity news, oil traded up 0.4% to $72.53 while gold traded up 0.6% at $2,954.40.
Silver traded up 1.2% to $33.425 on Thursday, while copper rose 1% to $4.6080.
Euro zone
European shares closed mixed today. The eurozone's STOXX 600 fell 0.20%, Germany's DAX 40 fell 0.53% and France's CAC 40 gained 0.15%. Spain's IBEX 35 Index rose 0.3%, while London's FTSE 100 fell 0.57%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 1.24%, China's Shanghai Composite Index falling 0.02%, Hong Kong's Hang Seng Index falling 1.60% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The EIA said crude oil inventories in the U.S. climbed by 4.633 million barrels in the week ended Feb. 14, compared to market estimates of a 3 million gain.</li>
<li>Initial jobless claims increased by 5,000 from the prior week to 219,000 in the week ending Feb. 15, versus estimates of 215,000.</li>
<li>The Philadelphia Fed Manufacturing Index fell to 18.1 in February from 44.3 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43851159/how-to-earn-500-a-month-from-newmont-stock-ahead-q4-earnings">How To Earn $500 A Month From Newmont Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

CYCU

MNDR

MTLS

SOAR

Dow Dips Over 1%; Walmart Shares Plunge Following Soft Guidance

Investors with a lot of money to spend have taken a bearish stance on Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NEM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 35 uncommon options trades for Newmont.
This isn't normal.
The overall sentiment of these big-money traders is split between 28% bullish and 65%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $1,495,555, and 24 are calls, for a total amount of $1,685,361.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $65.0 for Newmont over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Newmont's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Newmont's significant trades, within a strike price range of $35.0 to $65.0, over the past month.
<h3>Newmont Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740082533_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.36</td>
<td>$1.31</td>
<td>$1.31</td>
<td>$50.00</td>
<td>$655.0K</td>
<td>26.9K</td>
<td align="right">953</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.25</td>
<td>$18.15</td>
<td>$18.25</td>
<td>$65.00</td>
<td>$381.4K</td>
<td>137</td>
<td align="right">1</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.0</td>
<td>$15.95</td>
<td>$16.0</td>
<td>$62.50</td>
<td>$249.6K</td>
<td>0</td>
<td align="right">0</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.3</td>
<td>$2.2</td>
<td>$2.21</td>
<td>$52.50</td>
<td>$232.0K</td>
<td>2.3K</td>
<td align="right">45</td>
</tr>
<tr>
<td>NEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.95</td>
<td>$13.9</td>
<td>$13.9</td>
<td>$60.00</td>
<td>$180.7K</td>
<td>802</td>
<td align="right">131</td>
</tr>
</tbody>
</table>

<h3>About Newmont</h3>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
<h3>Where Is Newmont Standing Right Now?</h3>
<ul>
<li>With a volume of 7,445,319, the price of NEM is up 1.61% at $48.17. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Newmont with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Looking At Newmont's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SCHW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Charles Schwab. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 11% leaning bullish and 55% bearish. Among these notable options, 5 are puts, totaling $259,396, and 4 are calls, amounting to $330,167.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $85.0 for Charles Schwab, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Charles Schwab options trades today is 1945.8 with a total volume of 15,643.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Charles Schwab's big money trades within a strike price range of $80.0 to $85.0 over the last 30 days.
<h3>Charles Schwab Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740082528_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.03</td>
<td>$1.0</td>
<td>$1.03</td>
<td>$85.00</td>
<td>$123.7K</td>
<td>4.1K</td>
<td>1.2K</td>
</tr>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$1.28</td>
<td>$1.12</td>
<td>$1.15</td>
<td>$84.00</td>
<td>$116.8K</td>
<td>37</td>
<td>0</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$0.55</td>
<td>$0.52</td>
<td>$0.52</td>
<td>$80.00</td>
<td>$113.4K</td>
<td>568</td>
<td>2.3K</td>
</tr>
<tr>
<td>SCHW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.01</td>
<td>$1.0</td>
<td>$1.01</td>
<td>$85.00</td>
<td>$63.1K</td>
<td>4.1K</td>
<td>1.8K</td>
</tr>
<tr>
<td>SCHW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$0.57</td>
<td>$0.5</td>
<td>$0.54</td>
<td>$80.00</td>
<td>$54.0K</td>
<td>568</td>
<td>2.9K</td>
</tr>
</tbody>
</table>

<h3>About Charles Schwab</h3>
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $9 trillion of client assets at the end of September 2024. Nearly all of its revenue is from the United States.
<h3>Present Market Standing of Charles Schwab</h3>
<ul>
<li>Trading volume stands at 6,191,624, with SCHW's price down by -0.63%, positioned at $81.5.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 53 days.</li>
</ul>
<h3>What Analysts Are Saying About Charles Schwab</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $95.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Wells Fargo upgrades its rating to Overweight with a revised price target of $93. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Charles Schwab, which currently sits at a price target of $96. 
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $90. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Charles Schwab, which currently sits at a price target of $91. 
&#x2A; An analyst from Deutsche Bank persists with their Buy rating on Charles Schwab, maintaining a target price of $105. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Charles Schwab, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

SCHW

Looking At Charles Schwab's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bullish approach towards Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ENVX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Enovix. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $275,628, and 5 are calls, amounting to $281,744.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $8.0 to $17.0 for Enovix over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Enovix's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Enovix's substantial trades, within a strike price spectrum from $8.0 to $17.0 over the preceding 30 days.
<h3>Enovix Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740082522_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$5.6</td>
<td>$5.45</td>
<td>$5.45</td>
<td>$15.00</td>
<td>$143.3K</td>
<td>0</td>
<td align="right">163</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.85</td>
<td>$3.75</td>
<td>$3.75</td>
<td>$9.00</td>
<td>$90.3K</td>
<td>81</td>
<td align="right">242</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$5.55</td>
<td>$5.45</td>
<td>$5.45</td>
<td>$15.00</td>
<td>$87.2K</td>
<td>0</td>
<td align="right">163</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$3.85</td>
<td>$3.7</td>
<td>$3.75</td>
<td>$10.00</td>
<td>$72.3K</td>
<td>23</td>
<td align="right">1</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.45</td>
<td>$2.45</td>
<td>$2.45</td>
<td>$15.00</td>
<td>$49.0K</td>
<td>15.0K</td>
<td align="right">283</td>
</tr>
</tbody>
</table>

<h3>About Enovix</h3>
Enovix Corp is engaged in the business of advanced silicon-anode lithium-ion battery development and production. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable the widespread utilization of renewable energy.
After a thorough review of the options trading surrounding Enovix, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Enovix</h3>
<ul>
<li>With a trading volume of 8,261,944, the price of ENVX is down by -8.22%, reaching $10.27.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 69 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Enovix</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $24.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Craig-Hallum has decided to maintain their Buy rating on Enovix, which currently sits at a price target of $18. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $30. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Enovix with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

ENVX

What the Options Market Tells Us About Enovix

W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) has outperformed the market over the past 5 years by 14.93% on an annualized basis producing an average annual return of 29.22%. Currently, W.W. Grainger has a market capitalization of $49.97 billion. 
Buying $1000 In GWW: If an investor had bought $1000 of GWW stock 5 years ago, it would be worth $3,466.07 today based on a price of $1026.10 for GWW at the time of writing.
<h3>W.W. Grainger's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740082509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In W.W. Grainger 5 Years Ago Would Be Worth This Much Today

WIIM

Bausch Health shares are trading higher after the company reported better-than-expected Q4 sales.

WeRide shares are trading lower on possible profit-taking after gaining last week when Nvidia disclosed a 1.74 million share stake in a 13F filing.

Like clockwork, Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) posted strong earnings results, delivering fourth-quarter adjusted earnings per share of 66 cents on top of revenue of $180.55 billion. Both figures beat their respective analyst consensus targets of 64 cents and $180.01 billion. Unfortunately, the one avenue that disappointed Wall Street was the <a href="https://www.benzinga.com/news/earnings/25/02/43846469/walmart-q4-earnings-shine-but-soft-fy26-outlook-disappoints-street">forward guidance</a>, sending the stock tumbling down.
To be sure, <a href="https://www.benzinga.com/quote/WMT/earnings">earnings misses themselves are rare</a>. Going back to May 2020, Walmart has only failed to meet analysts' estimates twice. In terms of revenue, the big-box retailer has a perfect record during the aforementioned period. However, concerns over the stock — particularly due to macroeconomic or geopolitical events — are nothing new. This framework may offer hope amid the current downbeat news.
Isolated to just the fourth-quarter results, the storyline appears quite optimistic. For example, Walmart's gross margin rate was up 53 basis points, thanks in large part to its core domestic business. Operating income increased by 8.3% to about $600 billion. Further, same-store sales for Walmart U.S. climbed by 4.6%, excluding fuel.
However, management disclosed that first-quarter adjusted EPS may only land between 57 cents and 58 cents, noticeably below the estimate of 64 cents. For fiscal year 2026, adjusted EPS may range between $2.50 to $2.60, below analysts' consensus view of $2.76. Naturally, <a href="https://www.benzinga.com/markets/equities/25/02/43811296/walmart-set-for-record-sales-amid-tariff-concerns-one-of-the-better-positioned-retailers-to-mitigate-or-manage-through-tariffs-says-analyst">new tariffs</a> introduced by President Donald Trump on goods produced in China, India, Mexico and Canada weighed heavily on investors.
Nevertheless, it's important to remember that in May 2019, Walmart warned that prices would <a href="https://www.reuters.com/article/business/walmart-says-higher-china-tariffs-will-increase-prices-for-us-shoppers-idUSKCN1SM18X/">rise</a> due to the trade war at the time with China. Such disclosures ultimately didn't hurt the stock. That may have been for the reasons UBS analyst Michael Lasser is providing now for why the retailer could be resilient: "price leadership, buying power, and global sourcing capabilities."
<h2 class="wp-block-heading">Historical Price Trends Suggest Volatility In Walmart Stock As A Discount</h2>
Perhaps the sweetest irony amid the red ink is that Walmart — the leader of the everyday low-pricing business model — is now offering a discount on its own equity. Typically, volatility represents a warning sign. However, for a relevant behemoth like Walmart, the downside has consistently shown itself to be a discounted opportunity.
Primarily, long-side speculators largely benefit from the upward bias of Walmart stock. Using data since January 2019, a purely stochastic or temporal view of Walmart reveals that a position entered at the beginning of the week has about a 55.2% chance of rising by the end of it. Over the next four weeks, the long odds actually rise to over 62%.
However, something interesting happens when Walmart stock encounters unusual volatility. For the current week, the security is on pace to lose more than 6%. Whenever Walmart incurs a one-week loss between 5% and 10%, the subsequent week sees long odds pop to nearly 67%. This stat stays consistent for the next four weeks, resulting in a median return (assuming the positive scenario) of 2.89%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20140807/WMT-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-791673" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20140807/WMT-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20140807/WMT-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20140807/WMT-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20140807/WMT-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
To be fair, such big losses in Walmart stock are rare: it's only happened six times since January 2019 so the dataset is extremely small. However, if Walmart manages to mitigate the weekly red ink to below 5%, the odds would still favor the long-side speculator. Over the next four weeks following modest volatility, the long odds are still around 62%.
While historical trends aren't guaranteed to repeat, the optimistic view — despite tariff fears — makes sense. Walmart doesn't just exercise scale and pricing power, which are enormous advantages to begin with. For years, it has also <a href="https://www.retaildive.com/news/walmart-reportedly-pushing-for-higher-margin-goods-to-boost-online-profits/516646/">diversified</a> into higher-margin goods, which was reflected in the fourth-quarter report.
<h2 class="wp-block-heading">A Bold Options Strategy to Consider</h2>
Given the bounce-back tendencies of Walmart&#8217;s stock, buy-and-hold investors may consider the present dip as a possible entry point. For aggressive traders, the red ink is arguably more compelling. With so much fear baked into the forward guidance and the impact of tariffs, Walmart call options appear relatively underpriced.
The most daring traders may consider a multi-leg options strategy called the <a href="https://www.benzinga.com/money/bull-spread">bull call spread</a> for the options chain expiring March 21; specifically, the 97.50/100 bull spread. This transaction calls for buying the $97.50 call and simultaneously selling the $100 call. By taking the proceeds from the short call, the trader partially offsets the debit paid for the long call.
At time of writing, the net debit required for this trade is $109, which is also the most that can be lost. On the other end, the maximum reward possible is $141 or a payout of over 129%. Share prices will need to rise by over 2.8% at expiration to hit the $100 short-strike target, thus triggering the payout.
To note, bull call spreads are capped-risk, capped-reward transactions. The lower-priced long call meets the potential obligation implied by the higher-priced short call. However, many traders are willing to engage such transactions because it allows them to potentially profit handsomely from relatively small moves in the underlying equity.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43862827/this-palantir-technologies-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday">This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday</a></li>
</ul>
Image: Shutterstock

Earnings Beats

Long Ideas

Movers

Options Corner: Walmart's Best Rollback Could Be For Its Own Shares

Trading in Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) is flat Thursday. This follows yesterday&#8217;s gain of over 21% which was driven by an <a href="https://www.benzinga.com/news/earnings/earnings-beats/25/02/43855595/analog-devices-posts-q4-beat-industry-shows-early-signs-cyclical-recovery-analysts">earnings release</a>.
It isn't a surprise the rally stalled out where it did. Stocks frequently hit resistance at price levels that had been resistance before. That's the case with Analog and the $242 level.
Good traders can recognize which price levels are important in markets. They know that when a stock reaches one of these levels, the tendency is for them to either reverse, break out, or break down. These are called support and resistance levels.
Back in May when ADI reached $242, the sellers came out of the woodwork. They overpowered the buyers and pushed the price lower.
When this happened, many of the traders and investors who bought shares around $242 came to believe their decision to buy was a mistake. Some of them decided to sell their shares, but they didn't want to lose money.
As a result, they made the decision to hold onto their shares and eventually sell if they can get out at breakeven. So, when the stock returned to $242.00 in July they placed sell orders. This large concentration of these orders created resistance at the same price that had been resistance before.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20150030/120-1024x547.png" alt="" class="wp-image-791787" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20150030/120-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20150030/120-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20150030/120-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20150030/120.png 1518w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/25/02/43858501/whats-moving-markets-thursday">Palantir Rally Loses Steam, Walmart Outlook Disappoints: What&#8217;s Driving Markets Thursday?</a>
Now that the price has returned to this level, a similar dynamic is occurring. People who bought shares around $242 in July are placing sell orders so they can finally exit the position at breakeven. Buyer remorse has once again caused resistance to form at a price that had previously been resistance.
When stocks reach important resistance levels, they tend not to stay at them for an extended period of time. They tend to either reverse and sell off, or break out and move higher.
This is why Analog is on the radar screen of many traders as a possible idea.
If the resistance breaks and the shares move higher, this will mean that the sellers have left the market. They have finished or canceled.&nbsp; This could be a setup for another bullish move.
If buyers enter the market, they may have a tough time finding someone to buy shares from. They may need to push the price higher to draw sellers back into the market. This could force an uptrend to form.
If the resistance doesn't break, sellers may fear missing out and reduce the prices they are willing to sell for. If they start to undercut each other this could force a downtrend to form.
Important price levels are like a fork in the road. When stocks reach them, they tend to go one way or another. Some savvy traders are waiting to see which way Analog Devices will trend before they take positions.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43861405/dave-portnoy-calls-for-a-crypto-cleanup-but-heres-what-could-make-that-tricky">Dave Portnoy Calls For A &#8216;Crypto Cleanup,&#8217; But Here&#8217;s What Could Make That Tricky</a></li>
</ul>
Image: Shutterstock

Technicals

Stock Of The Day: Is Analog Devices Due For Breakout Or Breakdown?

Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $295.13, a high estimate of $350.00, and a low estimate of $245.00. This upward trend is apparent, with the current average reflecting a 7.06% increase from the previous average price target of $275.67.
<img src="https://www.benzinga.com/files/images/story/2025/1740081694_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Carvana by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$277.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$330.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$245.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Carvana. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Carvana compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Carvana's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Carvana's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CVNA/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Carvana analyst ratings.</a>
<h2>Delving into Carvana's Background</h2>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
<h3>Carvana: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Carvana's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 31.81%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Carvana's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.33% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 14.95%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: Carvana's debt-to-equity ratio is notably higher than the industry average. With a ratio of 10.06, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CVNA

What 15 Analyst Ratings Have To Say About Carvana

In the preceding three months, 9 analysts have released ratings for Clean Harbors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $270.33, a high estimate of $290.00, and a low estimate of $254.00. Highlighting a 0.94% decrease, the current average has fallen from the previous average price target of $272.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1740081683_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Clean Harbors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$254.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$284.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$272.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$268.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$268.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$256.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Michael Hoffman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Clean Harbors. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clean Harbors compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Clean Harbors's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Clean Harbors's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLH/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Clean Harbors analyst ratings.</a>
<h2>Delving into Clean Harbors's Background</h2>
Clean Harbors Inc is an environmental and industrial services provider. It provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. The company generates the majority of its revenues from the Environmental Services segment.
<h3>Unraveling the Financial Story of Clean Harbors</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Clean Harbors's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.99% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Clean Harbors's net margin excels beyond industry benchmarks, reaching 7.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Clean Harbors's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.64%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.6%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.2.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Clean Harbors's Future

OneSpaWorld shares are trading lower after the company on Wednesday reported a Q4 adjusted EPS miss and issued Q1 revenue guidance below estimates.

During the last three months, 7 analysts shared their evaluations of Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $71.14, a high estimate of $86.00, and a low estimate of $65.00. This current average represents a 0.5% decrease from the previous average price target of $71.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740081673_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Exact Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Exact Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exact Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>All You Need to Know About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Exact Sciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 12.78%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exact Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -5.4%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Exact Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of -1.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exact Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXAS

Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts

Ratings for Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $217.33, a high estimate of $221.00, and a low estimate of $212.00. Surpassing the previous average price target of $215.75, the current average has increased by 0.73%.
<img src="https://www.benzinga.com/files/images/story/2025/1740081666_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Krystal Biotech by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$215.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$218.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$221.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$212.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$221.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$221.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$212.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$221.00</td>
<td>$221.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Krystal Biotech. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Krystal Biotech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Krystal Biotech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Krystal Biotech's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KRYS/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Krystal Biotech analyst ratings.</a>
<h2>About Krystal Biotech</h2>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Financial Milestones: Krystal Biotech's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Krystal Biotech's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 879.91%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Krystal Biotech's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 32.42% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Krystal Biotech's ROE stands out, surpassing industry averages. With an impressive ROE of 3.15%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Krystal Biotech's ROA stands out, surpassing industry averages. With an impressive ROA of 2.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

A Glimpse Into The Expert Outlook On Krystal Biotech Through 9 Analysts

Microvast Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NYSE">MVST</a>) short percent of float has fallen 3.68% since its last report. The company recently reported that it has 16.38 million shares sold short, which is 15.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Microvast Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740081663_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Microvast Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Microvast Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Microvast Holdings's peer group average for short interest as a percentage of float is 5.04%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

MVST

How Is The Market Feeling About Microvast Holdings?

Credo Technology Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NYSE">CRDO</a>) short percent of float has fallen 10.51% since its last report. The company recently reported that it has 6.96 million shares sold short, which is 4.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Credo Technology Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740081657_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Credo Technology Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Credo Technology Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Credo Technology Group's peer group average for short interest as a percentage of float is 5.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CRDO

Is the Market Bullish or Bearish on Credo Technology Group?

Press Releases

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 14th + KARMAN POPS DOUBLE DIGIT IPO

KRMN

Karman Holdings

IPOs

Karman IPO Price Opens At $30.225/Share; IPO Priced At $22/Share On 23M Shares

Rumors

Karman IPO Price Indicating $30/Share On 806,744 Shares; IPO Priced At $22/Share On 23M Shares

Karman IPO Price Indicating $28/Share On 600K Shares; IPO Priced At $22/Share On 23M Shares

Karman Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) IPO will take place February, 14 on the NYSE exchange under the ticker KRMN.
The company is offering shares at an expected price between $18.00 and $20.00 per share with an insider lock-up period of 180 days ending on August 13, 2025.
See also: <a href="https://www.benzinga.com/calendars/ipos">Benzinga IPO Calendar</a>
<h3>About Karman Holdings Inc</h3>
Karman Holdings Inc is specialize in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile, missile and defense, and space programs
See also: <a href="https://www.benzinga.com/short-interest">Benzinga's Most Shorted Stocks</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Karman Holdings Inc To Start Trading Tomorrow

Comments

Karman Holdings

News

Latest news for Karman Holdings (NYSE:KRMN) Stock

Thursday, February 13, 2025

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga